Compare · ARVN vs NRIX
ARVN vs NRIX
Side-by-side comparison of Arvinas Inc. (ARVN) and Nurix Therapeutics Inc. (NRIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARVN and NRIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NRIX is the larger of the two at $1.40B, about 3.3x ARVN ($423.0M).
- NRIX has been more active in the news (15 items in the past 4 weeks vs 9 for ARVN).
- ARVN has more recent analyst coverage (25 ratings vs 20 for NRIX).
- Company
- Arvinas Inc.
- Nurix Therapeutics Inc.
- Price
- -
- -
- Market cap
- $423.0M
- $1.40B
- 1M return
- -
- -49.63%
- 1Y return
- -
- -25.06%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 9
- 15
- Recent ratings
- 25
- 20
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Nurix Therapeutics Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Latest ARVN
- GeneDx Announces Leadership Transition
- SEC Form EFFECT filed by Arvinas Inc.
- Arvinas to Present at Jefferies Global Healthcare Conference
- VP, Chief Accounting Officer Loomis David K sold $1,475 worth of shares (232 units at $6.36), decreasing direct ownership by 0.58% to 39,961 units (SEC Form 4) (withholding tax)
- Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
- SEC Form S-3 filed by Arvinas Inc.
- SEC Form 10-Q filed by Arvinas Inc.
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Latest NRIX
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
- Nurix Therapeutics to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.
- Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
- Chief Financial Officer Van Houte Hans sold $74,562 worth of shares (4,769 units at $15.63) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 42,745 units (SEC Form 4)
- Chief Legal Officer Ring Christine exercised 5,786 shares at a strike of $8.72 and sold $431,904 worth of shares (16,715 units at $25.84) as part of a pre-agreed trading plan, decreasing direct ownership by 71% to 4,406 units (SEC Form 4)